WXIBF (WXIBF) Stock Price & Analysis
WXIBF (WXIBF) rose 0.00% to USD 4.6 as of July 25, 2026 at 03:44 UTC, according to Nexqual real-time market data.
WXIBF last closed at USD 4.6; the session ranged USD 4.6–4.6 on volume of 1,557 shares. Market capitalization is $18.89B, with a 52-week range of USD 3.8–5.61 (PNK). Source: Nexqual, July 25, 2026 at 03:44 UTC.
Key Statistics (as of July 25, 2026 at 03:44 UTC)
| Price | USD 4.6 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 4.6 |
| Open | USD 4.6 |
| Day Range | USD 4.6 – 4.6 |
| 52-Week Range | USD 3.8 – 5.61 |
| Volume | 1,557 shares |
| Market Cap | $18.89B |
| Exchange | PNK |
Technical Analysis (WXIBF)
Nexqual's technical model rates WXIBF "STRONG BUY" based on 6 bullish and 0 bearish signals across 124 daily candles, as of July 25, 2026 at 03:44 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 61.54 (neutral) |
| vs SMA50 | Above (USD 4.34) |
| MACD | 0.09 (positive) |
Analyst Ratings (WXIBF)
Wall Street analysts rate WXIBF "None", per Nexqual as of July 25, 2026 at 03:44 UTC.
| Consensus Rating | None |
|---|
Earnings (WXIBF)
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Financials & Fundamentals (WXIBF)
| Total Revenue | $21.79B |
|---|---|
| Revenue Growth (YoY) | +17.20% |
| Gross Margin | +45.98% |
| Operating Margin | +33.14% |
| Profit Margin | +22.53% |
| ROE | +11.64% |
| Debt / Equity | 5.85 |
| Current Ratio | 3.39 |
| Total Cash | $15.73B |
| Total Debt | $3.10B |
| Free Cash Flow | $4.28B |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Financial Health Score (WXIBF)
Nexqual rates WXIBF's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 03:44 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 46%, operating 33% |
| Balance Sheet | Strong — $15.7B cash vs $3.10B debt, net cash position |
| Cash Flow | Strong — FCF $4.28B, 20% margin |
| Efficiency | Mixed — ROE 12%, ROA 6.9% |
Ownership (WXIBF)
| Insider Ownership | +9.99% |
|---|---|
| Institutional Ownership | +39.33% |
| Shares Outstanding | 4.11B |
| Float | 3.73B |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Leadership (WXIBF)
WXIBF is led by Zhisheng Chen (age 52), CEO & Executive Director, per Nexqual as of July 25, 2026 at 03:44 UTC.
| CEO & Executive Director | Zhisheng Chen (age 52) |
|---|---|
| Founder & Chairman | Ge Li (age 58) |
| CFO & Executive VP | Ming Tu (age 56) |
| COO & Senior VP | Lihua Yu |
| Chief Scientific Officer & President of Global Biologics Research | Jijie Gu (age 59) |
Major Backers & Investors (WXIBF)
Notable institutional backers of WXIBF include Baird Funds Inc-Baird Chautauqua International Growth Fund, J.P. Morgan Exch-Trd Fd. TRT-JPMorgan BetaBuilders Developed Asia Paci, DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT., according to Nexqual as of July 25, 2026 at 03:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baird Funds Inc-Baird Chautauqua International Growth Fund | 0.26% |
| J.P. Morgan Exch-Trd Fd. TRT-JPMorgan BetaBuilders Developed Asia Paci | 0.24% |
| DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT. | 0.24% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.04% |
| BlackRock | 1.36% |
Source: Nexqual, July 25, 2026 at 03:44 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WXXWY | Wuxi Biologics (Cayman) Inc | USD 9.89 | ▼ 0.2% |
| CMXHF | CSL Ltd. | USD 81.96 | ▲ 0% |
| UCBJY | UCB S.A. | USD 139.01 | ▼ 0.04% |
| GNMSF | Genmab A/S | USD 274.5 | ▲ 0% |
| CSLLY | CSL Ltd. | USD 20 | ▼ 3.85% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:44 UTC. This page is informational and not investment advice.